Larimar Therapeutics, Inc.

LRMR
$3.44 (- $0.06 - 1.71%)
Last updated: 2026-06-10 20:30 UTC
LRMR Metrics
Exchange
🇺🇸 NASDAQ XNMS
Nasdaq/NMS (Global Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS5171251003
CUSIP517125100
Market Price3.44
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-1.96
Market Cap$339.8M
Book Value1.62
Price to Book2.445
Beta1.05
52w High5.37
52w Low1.61
Next Earnings DateN/A

Larimar Therapeutics, Inc. trades under ticker LRMR on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US5171251003, CUSIP 517125100.

About the Company
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Price History